To the full analysis
Buyback calculator for Haisco Pharmaceutical Group
Haisco Pharmaceutical Group stock: key metrics
002653.SZHaisco Pharmaceutical Group had an operating margin of 4% and a return on invested capital (ROIC) of 3.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2008 | 69.5% | 58.2% | 54.4% |
| 2009 | 70.9% | 55.6% | 58.6% |
| 2010 | 65.7% | 50.0% | 52.6% |
| 2011 | 66.8% | 46.5% | 51.7% |
| 2012 | 74.5% | 40.0% | 55.2% |
| 2013 | 72.9% | 46.5% | 52.3% |
| 2014 | 69.7% | 37.5% | 37.2% |
| 2015 | 66.9% | 33.4% | 30.7% |
| 2016 | 74.1% | 23.1% | 30.8% |
| 2017 | 64.5% | 14.3% | 12.8% |
| 2018 | 56.4% | 9.5% | 9.7% |
| 2019 | 65.8% | 13.9% | 12.5% |
| 2020 | 67.9% | 21.0% | 19.1% |
| 2021 | 65.9% | 18.5% | 12.4% |
| 2022 | 69.3% | 12.1% | 9.2% |
| 2023 | 71.1% | 9.3% | 8.8% |
| 2024 | 71.5% | 13.6% | 10.6% |
| 2025 | 69.5% | 4.0% | 6.0% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2008 | 90.8% | 129.7% | 55.2% |
| 2009 | 200.0% | 282.8% | 81.2% |
| 2010 | 67.5% | 74.4% | 48.5% |
| 2011 | 40.7% | 128.9% | 35.4% |
| 2012 | 25.9% | 80.3% | 22.8% |
| 2013 | 26.9% | 67.9% | 21.1% |
| 2014 | 21.4% | 58.1% | 15.7% |
| 2015 | 17.3% | 32.7% | 11.5% |
| 2016 | 19.7% | 17.3% | 11.8% |
| 2017 | 12.0% | 14.1% | 5.8% |
| 2018 | 16.4% | 18.9% | 7.6% |
| 2019 | 20.8% | 25.1% | 9.8% |
| 2020 | 21.9% | 24.4% | 12.7% |
| 2021 | 12.1% | 16.1% | 6.9% |
| 2022 | 9.1% | 9.8% | 4.6% |
| 2023 | 7.1% | 7.7% | 4.4% |
| 2024 | 9.4% | 12.7% | 5.8% |
| 2025 | 6.1% | 3.7% | 3.7% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- Valuation signal Overvalued since 8 Nov 2026, previously Fairly valued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.